• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of amjpatholAmerican Journal of Pathology For AuthorsAmerican Journal of Pathology SubscribeAmerican Journal of Pathology SearchAmerican Journal of Pathology Current IssueAmerican Journal of Pathology About the JournalAmerican Journal of Pathology
Am J Pathol. Sep 1993; 143(3): 972–982.
PMCID: PMC1887192

A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice.


Chronic proliferative dermatitis is a new spontaneous mutation in C57BL/Ka mice. Breeding results suggest an autosomal recessive mode of inheritance. Mutant mice develop skin lesions at the age of 5 to 6 weeks. The lesions occur in the ventral and dorsal skin of the body, whereas ears, footpads, and tail are not involved. The lesions are characterized by epidermal hyperplasia, hyper- and parakeratosis, and single cell necrosis of keratinocytes. The dermis and epidermis are infiltrated by granulocytes and macrophages, and occasionally subcorneal and intracorneal microabscesses are formed. The number of mast cells in the dermis progressively increases with age. There is dilatation and proliferation of dermal capillaries. Similar lesions develop in the mouth, esophagus, and forestomach, which, in the mouse, are all lined by orthokeratinizing stratified squamous cell epithelium. Studies with bromodeoxyuridine confirm the increased rate of epithelial cell proliferation. Most inflammatory cells in the affected skin express Mac-1, and few express the T lymphocyte marker CD3. There is increased expression of intracellular adhesion molecule-1 on keratinocytes and endothelial cells. Infiltration of neutrophils and macrophages are also seen in the liver, lung, and several joints. The disease could not be transferred by bone marrow or spleen transplants into irradiated normal syngeneic hosts. Treatment of the mice with triamcinolone, a long-acting corticosteroid, resulted in nearly complete regression of the lesions over a period of 4 weeks, whereas systemic cyclosporin A treatment was ineffective.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Darling SM, Abbott CM. Mouse models of human single gene disorders. I: Nontransgenic mice. Bioessays. 1992 Jun;14(6):359–366. [PubMed]
  • Sundberg JP, Beamer WG, Shultz LD, Dunstan RW. Inherited mouse mutations as models of human adnexal, cornification, and papulosquamous dermatoses. J Invest Dermatol. 1990 Nov;95(5):62S–63S. [PubMed]
  • Horley KJ, Carpenito C, Baker B, Takei F. Molecular cloning of murine intercellular adhesion molecule (ICAM-1). EMBO J. 1989 Oct;8(10):2889–2896. [PMC free article] [PubMed]
  • Kraal G, Breel M, Janse M, Bruin G. Langerhans' cells, veiled cells, and interdigitating cells in the mouse recognized by a monoclonal antibody. J Exp Med. 1986 Apr 1;163(4):981–997. [PMC free article] [PubMed]
  • Paus R, Stenn KS, Link RE. The induction of anagen hair growth in telogen mouse skin by cyclosporine A administration. Lab Invest. 1989 Mar;60(3):365–369. [PubMed]
  • Brown WR, Hardy MH. A hypothesis on the cause of chronic epidermal hyperproliferation in asebia mice. Clin Exp Dermatol. 1988 Mar;13(2):74–77. [PubMed]
  • Vassar R, Fuchs E. Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. Genes Dev. 1991 May;5(5):714–727. [PubMed]
  • Leonard JM, Abramczuk JW, Pezen DS, Rutledge R, Belcher JH, Hakim F, Shearer G, Lamperth L, Travis W, Fredrickson T, et al. Development of disease and virus recovery in transgenic mice containing HIV proviral DNA. Science. 1988 Dec 23;242(4886):1665–1670. [PubMed]
  • Bailleul B, Surani MA, White S, Barton SC, Brown K, Blessing M, Jorcano J, Balmain A. Skin hyperkeratosis and papilloma formation in transgenic mice expressing a ras oncogene from a suprabasal keratin promoter. Cell. 1990 Aug 24;62(4):697–708. [PubMed]
  • Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell. 1990 Jun 29;61(7):1315–1327. [PubMed]
  • Lowe NJ, Stoughton RB. Essential fatty acid deficient hairless mouse: a model of chronic epidermal hyperproliferation. Br J Dermatol. 1977 Feb;96(2):155–162. [PubMed]
  • Stowe HD, Wagner JL, Pick JR. A debilitating fatal murine dermatitis. Lab Anim Sci. 1971 Dec;21(6):892–897. [PubMed]
  • Krueger GG. A perspective of psoriasis as an aberration in skin modified to expression by the inflammatory/repair system. Immunol Ser. 1989;46:425–445. [PubMed]
  • Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol. 1992 Jan;126(1):1–9. [PubMed]
  • Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol. 1991 Jun;127(6):871–884. [PubMed]
  • Krueger GG, Jorgensen CM. Experimental models for psoriasis. J Invest Dermatol. 1990 Nov;95(5):56S–58S. [PubMed]
  • Saiag P, Coulomb B, Lebreton C, Bell E, Dubertret L. Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science. 1985 Nov 8;230(4726):669–672. [PubMed]
  • Barker JN, Mitra RS, Griffiths CE, Dixit VM, Nickoloff BJ. Keratinocytes as initiators of inflammation. Lancet. 1991 Jan 26;337(8735):211–214. [PubMed]
  • Baadsgaard O, Gupta AK, Taylor RS, Ellis CN, Voorhees JJ, Cooper KD. Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells. J Invest Dermatol. 1989 Feb;92(2):190–195. [PubMed]
  • Bieber T, Braun-Falco O. Distribution of CD1a-positive cells in psoriatic skin during the evolution of the lesions. Acta Derm Venereol. 1989;69(2):175–178. [PubMed]
  • Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol. 1988 Jul;107(1):321–331. [PMC free article] [PubMed]
  • Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC. Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest. 1989 Jun;83(6):2008–2017. [PMC free article] [PubMed]
  • Diamond MS, Staunton DE, de Fougerolles AR, Stacker SA, Garcia-Aguilar J, Hibbs ML, Springer TA. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol. 1990 Dec;111(6 Pt 2):3129–3139. [PMC free article] [PubMed]
  • Griffiths CE, Nickoloff BJ. Keratinocyte intercellular adhesion molecule-1 (ICAM-1) expression precedes dermal T lymphocytic infiltration in allergic contact dermatitis (Rhus dermatitis). Am J Pathol. 1989 Dec;135(6):1045–1053. [PMC free article] [PubMed]
  • Horrocks C, Duncan JI, Oliver AM, Thomson AW. Adhesion molecule expression in psoriatic skin lesions and the influence of cyclosporin A. Clin Exp Immunol. 1991 Apr;84(1):157–162. [PMC free article] [PubMed]
  • Barker JN, Sarma V, Mitra RS, Dixit VM, Nickoloff BJ. Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest. 1990 Feb;85(2):605–608. [PMC free article] [PubMed]
  • Pober JS, Gimbrone MA, Jr, Cotran RS, Reiss CS, Burakoff SJ, Fiers W, Ault KA. Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon. J Exp Med. 1983 Apr 1;157(4):1339–1353. [PMC free article] [PubMed]
  • Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol. 1984 Aug;83(2):88–90. [PubMed]
  • Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991 Dec 20;67(6):1033–1036. [PubMed]
  • Kishimoto TK, Jutila MA, Berg EL, Butcher EC. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science. 1989 Sep 15;245(4923):1238–1241. [PubMed]
  • Piguet PF, Grau GE, Vassalli P. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol. 1990 Jan;136(1):103–110. [PMC free article] [PubMed]
  • Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med. 1987 Nov 1;166(5):1280–1289. [PMC free article] [PubMed]
  • Enk AH, Katz SI. Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1398–1402. [PMC free article] [PubMed]
  • Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature. 1990 Jul 19;346(6281):274–276. [PubMed]
  • Galli SJ, Arizono N, Murakami T, Dvorak AM, Fox JG. Development of large numbers of mast cells at sites of idiopathic chronic dermatitis in genetically mast cell-deficient WBB6F1-W/Wv mice. Blood. 1987 Jun;69(6):1661–1666. [PubMed]
  • Marks R, Pongsehirun D, Saylan T. A method for the assay of topical corticosteroids. Br J Dermatol. 1973 Jan;88(1):69–74. [PubMed]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...